Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2007RD01 + saw palmetto lipidic extract is a **combination dietary supplement** investigated for the treatment of **benign prostatic hyperplasia (BPH)**. 2007RD01 is described as a "natural extract" (specific identity not disclosed in the available sources), while saw palmetto lipidic extract (Serenoa repens) is an extract from the berry of the American dwarf palm, rich in fatty acids and phytosterols. The combination is being researched to determine if it is more effective than saw palmetto alone in improving urinary symptoms in BPH patients. Saw palmetto extract is theorized to work primarily via **inhibition of 5-alpha-reductase** (decreasing conversion of testosterone to dihydrotestosterone), **antagonism at alpha-1 adrenoceptors, muscarinic cholinoceptors, and other receptors in the lower urinary tract**, and **anti-inflammatory activity**. The extract may also inhibit cyclooxygenase and lipoxygenase pathways, providing additional anti-inflammatory and anti-androgenic effects[2][6][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2007RD01 + saw palmetto lipidic extract.